(Q43966701)

28 November 2017

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial (English)

1 reference

28 November 2017

0 references

0 references

1 reference

1

Timo Erkinjuntti

1 reference

28 November 2017

Alexander Kurz

2

1 reference

28 November 2017

Serge Gauthier

3

1 reference

28 November 2017

Roger Bullock

4

1 reference

28 November 2017

Sean Lilienfeld

5

1 reference

28 November 2017

ChandrasekharRao Venkata Damaraju

6

1 reference

28 November 2017

language of work or name

English

0 references

publication date

1 April 2002

1 reference

28 November 2017

1 reference

28 November 2017

359

1 reference

28 November 2017

1283-1290

1 reference

28 November 2017

9314

1 reference

Prevalence and outcomes of vascular cognitive impairment

28 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908267-3

7 January 2021

Brain infarction and the clinical expression of Alzheimer disease. The Nun Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908267-3

7 January 2021

Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908267-3

7 January 2021

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908267-3

7 January 2021

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908267-3

7 January 2021

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908267-3

7 January 2021

Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908267-3

7 January 2021

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908267-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908267-3

1 reference

7 January 2021

A new rating scale for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908267-3

7 January 2021

Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908267-3

7 January 2021

Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908267-3

7 January 2021

The Neuropsychiatric Inventory: assessing psychopathology in dementia patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908267-3

7 January 2021

An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908267-3

7 January 2021

Use of donepezil for vascular dementia: preliminary clinical experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908267-3

7 January 2021

Sensitivity and specificity of newly proposed clinical criteria for possible vascular dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908267-3

7 January 2021

10.1016/S0140-6736(02)08267-3

Identifiers

DOI

1 reference

28 November 2017

1 reference